Effects of silencing RIP1 with siRNA on the biological behavior of the LoVo human colon cancer cell line

You,Hong‑Xia; Zhou,Yan‑Hong; Tan,Shi‑Yun; She,Tong‑Hui

doi:10.3892/ol.2014.2040

Effects of silencing RIP1 with siRNA on the biological behavior of the LoVo human colon cancer cell line

Authors:
- Hong‑Xia You
- Yan‑Hong Zhou
- Shi‑Yun Tan
- Tong‑Hui She
View Affiliations

Affiliations: Department of Gastroenterology, Hubei University of Science and Technology, Xianning, Hubei 437100, P.R. China, Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: April 7, 2014 https://doi.org/10.3892/ol.2014.2040
Pages: 2065-2072

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the effects of silencing RIP1 by small interfering RNA (siRNA) on the biological behavior of the LoVo human colorectal carcinoma cell line and to provide evidence for the feasibility of colorectal cancer gene therapy. LoVo cells were divided into the RIP1 siRNA group, the blank control group and the negative control group. Chemically synthesized siRNA targeting RIP1 (RIP1 siRNA) was transfected into LoVo cells. Following transfection of the RIP1‑targeted siRNA into the LoVo cells, the expression of the RIP1 gene was effectively inhibited. The results demonstrated that RIP1 effectively regulated the malignant biological behavior of the LoVo colon cancer cell line. Furthermore, the proliferation, motility and invasiveness of LoVo cells were inhibited by siRNA knockdown of RIP1. The results revealed that the RIP1 gene has an important role in the regulation of proliferation and apoptosis in colorectal carcinoma cells.

View Figures

View References

1	Boncheva V, Bonney SA, Brooks SE, Tangney M, O’Sullivan G, Mirnezami A and Guinn BA: New targets for the immunotherapy of colon cancer-does reactive disease hold the answer? Cancer Gene Ther. 20:157–168. 2013. View Article : Google Scholar : PubMed/NCBI
2	Antonic V, Stojadinovic A, Kester KE, Weina PJ, Brücher BL, Protic M, Avital I and Izadjoo M: Significance of infectious agents in colorectal cancer development. J Cancer. 4:227–240. 2013. View Article : Google Scholar
3	Van den Eynden GG, Majeed AW, Illemann M, Vermeulen PB, Bird NC, Høyer-Hansen G, Eefsen RL, Reynolds AR and Brodt P: The multifaceted role of the microenvironment in liver metastasis: biology and clinical implications. Cancer Res. 73:2031–2043. 2013.PubMed/NCBI
4	Meylan E and Tschopp J: The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci. 30:151–159. 2005. View Article : Google Scholar : PubMed/NCBI
5	Stanger BZ, Leder P, Lee TH, Kim E and Seed B: RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell. 81:513–523. 1995. View Article : Google Scholar : PubMed/NCBI
6	Ye YC, Wang HJ, Yu L, Tashiro S, Onodera S and Ikejima T: RIP1-mediated mitochondrial dysfunction and ROS production contributed to tumor necrosis factor alpha-induced L929 cell necroptosis and autophagy. Int Immunopharmacol. 14:674–682. 2012. View Article : Google Scholar : PubMed/NCBI
7	Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M and Tschopp J: RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol. 5:503–507. 2004. View Article : Google Scholar : PubMed/NCBI
8	Park YH, Jeong MS, Park HH and Jang SB: Formation of the death domain complex between FADD and RIP1 proteins in vitro. Biochim Biophys Acta. 1834:292–300. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lu JV and Walsh CM: Programmed necrosis and autophagy in immune function. Immunol Rev. 249:205–217. 2012. View Article : Google Scholar : PubMed/NCBI
10	O’Donnell MA, Hase H, Legarda D and Ting AT: NEMO inhibits programmed necrosis in an NFκB-independent manner by restraining RIP1. PLoS One. 7:e412382012.PubMed/NCBI
11	Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ and Leder P: The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 8:297–303. 1998. View Article : Google Scholar : PubMed/NCBI
12	Bellail AC, Olson JJ, Yang X, Chen ZJ and Hao C: A20 ubiquitin ligase-mediated polyubiquitination of RIP1 inhibits caspase-8 cleavage and TRAIL-induced apoptosis in glioblastoma. Cancer Discov. 2:140–155. 2012. View Article : Google Scholar : PubMed/NCBI
13	Festjens N, Vanden Berghe T, Cornelis S and Vandenabeele P: RIP1, a kinase on the crossroads of a cell’s decision to live or die. Cell Death Differ. 14:400–410. 2007.
14	Motavaf M, Safari S and Alavian SM: Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C. J Viral Hepat. 19:757–765. 2012. View Article : Google Scholar : PubMed/NCBI
15	Ghafouri-Fard S and Ghafouri-Fard S: siRNA and cancer immunotherapy. Immunotherapy. 4:907–917. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tan SY, You HX and Zhou YH: Effect of silencing RIP1 by specific siRNA on the biological behaviour of human colon cancer cell line LoVo. Chin J Clinicians (Electronic Edition). 7:3892–3896. 2013.(In Chinese).
17	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
18	US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 149:627–637. 2008. View Article : Google Scholar : PubMed/NCBI
19	Messick CA, Church J, Casey G and Kalady MF: Identification of the methylator (serrated) colorectal cancer phenotype through precursor serrated polyps. Dis Colon Rectum. 52:1535–1541. 2009. View Article : Google Scholar : PubMed/NCBI
20	Xie T, Peng W, Liu Y, Yan C, Maki J, Degterev A, Yuan J and Shi Y: Structural basis of RIP1 inhibition by necrostatins. Structure. 21:493–499. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zhang J, Zhang H, Li J, Rosenberg S, Zhang EC, Zhou X, Qin F and Farabaugh M: RIP1-mediated regulation of lymphocyte survival and death responses. Immunol Res. 51:227–236. 2011. View Article : Google Scholar : PubMed/NCBI
22	Osborn SL, Diehl G, Han SJ, Xue L, Kurd N, Hsieh K, Cado D, Robey EA and Winoto A: Fas-associated death domain (FADD) is a negative regulator of T-cell receptor-mediated necroptosis. Proc Natl Acad Sci USA. 107:13034–13039. 2010. View Article : Google Scholar : PubMed/NCBI
23	Yang Y, Xia F, Hermance N, Mabb A, Simonson S, Morrissey S, Gandhi P, Munson M, Miyamoto S and Kelliher MA: A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol. 31:2774–2786. 2011. View Article : Google Scholar : PubMed/NCBI
24	Kim SS, Ahn CH, Kang MR, Kim YR, Kim HS, Yoo NJ and Lee SH: Expression of CARD6, an NF-kappaB activator, in gastric, colorectal and oesophageal cancers. Pathology. 42:50–53. 2010. View Article : Google Scholar : PubMed/NCBI
25	Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J and Liu ZG: Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci USA. 109:5322–5327. 2012. View Article : Google Scholar : PubMed/NCBI
26	Dai S, Jiang L, Wang G, Zhou X, Wei X, Cheng H, Wu Z and Wei D: HSP70 interacts with TRAF2 and differentially regulates TNFalpha signalling in human colon cancer cells. J Cell Mol Med. 14:710–725. 2010.PubMed/NCBI
27	Verbrugge I and Johnstone RW: Regulating the TRAIL of destruction: how A20 protects glioblastomas from TRAIL-mediated death. Cancer Discov. 2:112–114. 2012. View Article : Google Scholar : PubMed/NCBI
28	Handke W, Krause E and Brune W: Live or let die: manipulation of cellular suicide programs by murine cytomegalovirus. Med Microbiol Immunol. 201:475–486. 2012. View Article : Google Scholar : PubMed/NCBI
29	Bist P, Leow SC, Phua QH, Shu S, Zhuang Q, Loh WT, Nguyen TH, Zhou JB, Hooi SC and Lim LH: Annexin-1 interacts with NEMO and RIP1 to constitutively activate IKK complex and NF-κB: implication in breast cancer metastasis. Oncogene. 30:3174–3185. 2011.PubMed/NCBI